TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26192328

Group type: EXPERIMENTAL
Intervention: Danshen (water-extract of Salvia Miltiorrhiza root)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23469870

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment (Group A, n=14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional instruments (Group B, n=14)
Number of subjects: 28
Study: 21247302

Group type: EXPERIMENTAL
Intervention: Drainage group (YD)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Nondrainage group (ND)
Number of subjects: 116
Study: 18804285

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) for depression
Number of subjects: 156
Study: 17154670

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0
Study: 14767273

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy plus interferon alpha‐2b
Number of subjects: 331

Group type: COMPARATOR
Intervention: Interferon alpha‐2b alone
Number of subjects: 331
Study: 11237928

Group type: EXPERIMENTAL
Intervention: Chlorogenic acid (2 g daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Black tea (4 g daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quercetin‐3‐rutinoside (440 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9251874

Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg sc)
Number of subjects: 424
Study: 8280556

Group type: EXPERIMENTAL
Intervention: Enoximone (loading dose of 0.5 mg kg‐1 followed by an infusion of 5 micrograms kg‐1 min‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Piroximone (loading dose of 0.5 mg kg‐1 followed by an infusion of 5 micrograms kg‐1 min‐1)
Number of subjects: 20
Study: 3502447

Group type: EXPERIMENTAL
Intervention: Chronic cerebellar stimulation (CCS)
Number of subjects: 30
Study: 30853117

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Hopelessness
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Central obesity
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Subjective recovery
Number of subjects: 263
Study: 28975710

Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 26974559

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral (CB) group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Complementary and Alternative Medicine - Cognitive Behavioral (CAM-CB) group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CAM-CB group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 56
Study: 24917119

Group type: EXPERIMENTAL
Intervention: Grintuss® pediatric syrup
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 22401329

Group type: EXPERIMENTAL
Intervention: Weekly automated telephone self-management (ATSM) support with nurse care management
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Monthly group medical visits (GMVs)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 330
Study: 20551827

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) commenced in winter
Number of subjects: 95

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation (PR) commenced in spring, summer, or autumn
Number of subjects: 95

Group type: COMPARATOR
Intervention: Incremental Shuttle Walking Test (ISWT) scores
Number of subjects: 95

Group type: COMPARATOR
Intervention: Chronic Respiratory Disease Questionnaire‐Self Reported
Number of subjects: 95
Study: 18657652

Group type: EXPERIMENTAL
Intervention: Verapamil-sustained release (SR) strategy
Number of subjects: 7218

Group type: COMPARATOR
Intervention: Atenolol-based strategy
Number of subjects: 7218
Study: 16317218

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg IV plus dexamethasone 20 mg (group A)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg IV plus dexamethasone 20 mg (group B)
Number of subjects: 39
Study: 12821974

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 11322152

Group type: EXPERIMENTAL
Intervention: Functional neuromuscular stimulation (FNS)
Number of subjects: 5

Group type: COMPARATOR
Intervention: No FNS (control)
Number of subjects: 5
Study: 8864768

Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of PHT and PB
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of CBZ and PB
Number of subjects: 32

Group type: COMPARATOR
Intervention: Drug-free (DF)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Normal healthy females (NS)
Number of subjects: 32
Study: 10121680

Group type: EXPERIMENTAL
Intervention: Videotapes
Number of subjects: 27

Group type: COMPARATOR
Intervention: Written summaries
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rating scale of videotapes
Number of subjects: 27
Study: 6383763

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg dipyridamole intravenously
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo intravenously
Number of subjects: 30
Study: 30414228

Group type: EXPERIMENTAL
Intervention: High obesity risk group (children with overweight/obese parents)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Low obesity risk group (children with normal-weight parents)
Number of subjects: 145
Study: 30113506

Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 26826459

Group type: EXPERIMENTAL
Intervention: Abdominal massage plus lifestyle advice
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lifestyle advice
Number of subjects: 32
Study: 24475198

Group type: EXPERIMENTAL
Intervention: Active case detection method (children monitored actively, visited twice weekly, tympanic temperature measured, malaria rapid diagnostic test performed if fever present)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive case detection method (children monitored passively, parents/caregivers asked to bring children to clinic if unwell)
Number of subjects: 0
Study: 21837394

Group type: EXPERIMENTAL
Intervention: Intranasal lorazepam (2 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Buccal lorazepam (2 mg)
Number of subjects: 12
Study: 20646129

Group type: EXPERIMENTAL
Intervention: Let's Face It! (LFI!) computer-based intervention, 20 hours of face training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 42
Study: 17208382

Group type: EXPERIMENTAL
Intervention: DHEA (titrated up to 150mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15650833

Group type: EXPERIMENTAL
Intervention: Home-based daily exercise therapy (20-min exercise program once per day for 8 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based daily exercise therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 12815801

Group type: EXPERIMENTAL
Intervention: Oral antihistamines and topical steroids
Number of subjects: 34
Study: 9672123

Group type: EXPERIMENTAL
Intervention: Naloxone (0.15 mg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 21
Study: 7728916

Group type: EXPERIMENTAL
Intervention: AVS plus intravenous immunoglobulin (IVIG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard AVS therapy
Number of subjects: 0
Study: 2547917

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 4
Study: 1200268

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No corticosteroids (Control)
Number of subjects: 50
Study: 31221218

Group type: EXPERIMENTAL
Intervention: Hybrid ablation
Number of subjects: 40

Group type: COMPARATOR
Intervention: (Repeated) catheter ablation
Number of subjects: 40
Study: 27845857

Group type: EXPERIMENTAL
Intervention: Planned health education (3 educational sessions at 2-week intervals)
Number of subjects: 247
Study: 25742794

Group type: EXPERIMENTAL
Intervention: Lidocaine with magnesium sulfate USP 50%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 100
Study: 23467275

Group type: EXPERIMENTAL
Intervention: G‐CSF (5 μg/kg per day, six doses) plus standard therapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard therapy only
Number of subjects: 55
Study: 21510270

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2)
Number of subjects: 232
Study: 19061203

Group type: EXPERIMENTAL
Intervention: Active treatment doses (specific doses not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 16813265

Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 90

Group type: COMPARATOR
Intervention: CSII
Number of subjects: 90

Group type: COMPARATOR
Intervention: IVII
Number of subjects: 90
Study: 12737682

Group type: EXPERIMENTAL
Intervention: Budesonide from PassCal Clickhaler (1,000 microg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide from Lactose Clickhaler (1,000 microg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide from Pulmicort Turbuhaler (1,000 microg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide from Pulmicort Turbuhaler (2,000 microg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10931049

Group type: EXPERIMENTAL
Intervention: Specialized leg ulcer clinics in East Gloucestershire
Number of subjects: 200

Group type: COMPARATOR
Intervention: West Gloucestershire control
Number of subjects: 200
Study: 8966826

Group type: EXPERIMENTAL
Intervention: Angiopeptin (750 micrograms/day)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 1410142

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (MCPP) 0.25 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (MCPP) 0.5 mg/kg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 17
Study: 2933926

Group type: COMPARATOR
Intervention: iohexol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: meglumine metrizoate
Number of subjects: 19
Study: 3318896

Group type: COMPARATOR
Intervention: Nalbuphine 10 mg ml‐1 (group N)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.15 mg ml‐1 (group B)
Number of subjects: 55
Study: 29241652

Group type: EXPERIMENTAL
Intervention: 100 μg roflumilast
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 28667397

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 16
Study: 25960304

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg/d
Number of subjects: 5466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5466
Study: 23805859

Group type: EXPERIMENTAL
Intervention: Naltrexone 25 mg/day
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 21164498

Group type: EXPERIMENTAL
Intervention: Olmesartan/HCTZ
Number of subjects: 207

Group type: COMPARATOR
Intervention: Olmesartan/Azelnidipine
Number of subjects: 207
Study: 19027483

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg per day orally)
Number of subjects: 1466

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 intravenously every 3 weeks)
Number of subjects: 1466

Group type: EXPERIMENTAL
Intervention: Gefitinib in patients with high EGFR-gene-copy number
Number of subjects: 1466

Group type: COMPARATOR
Intervention: Docetaxel in patients with high EGFR-gene-copy number
Number of subjects: 1466

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 1466

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1466
Study: 16585435

Group type: EXPERIMENTAL
Intervention: Risperidone (1.5-6.0 mg/day)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Olanzapine (7.5-30 mg/day)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Quetiapine (200-800 mg/day)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-160 mg/day)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 444

Group type: COMPARATOR
Intervention: Quetiapine and Ziprasidone
Number of subjects: 444
Study: 12631592

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with docetaxel plus doxorubicin or paclitaxel
Number of subjects: 15
Study: 11216491

Group type: EXPERIMENTAL
Intervention: 20 mg isoflavones
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 40 mg isoflavones
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20 mg and 40 mg isoflavones
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoflavone tablets
Number of subjects: 40
Study: 8828069

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at 10 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at 20 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at 40 mg/kg
Number of subjects: 17
Study: 1617765

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 686
Study: 3882526

Group type: EXPERIMENTAL
Intervention: Cisapride (0.5 mg/h intravenously, preceded by a three day oral loading at 10 mg tid)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 6
Study: 31227470

Group type: EXPERIMENTAL
Intervention: Supporting Cushions (SC)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Harmonic Techniques (HT)
Number of subjects: 22
Study: 29729825

Group type: EXPERIMENTAL
Intervention: Intensive nutrition intervention (individualized nutrition and exercise counselling; 12 dietitian visits; 3 exercise physiologist visits over 12 months)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard nutrition care (guideline based; 4 dietitian visits)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Overall cohort (both groups)
Number of subjects: 37
Study: 27977721

Group type: EXPERIMENTAL
Intervention: Miconazole nitrate mucoadhesive tablets (10 mg) once daily for 14 days
Number of subjects: 343

Group type: COMPARATOR
Intervention: Itraconazole capsules (100 mg QD) for 14 days
Number of subjects: 343
Study: 24413548

Group type: EXPERIMENTAL
Intervention: BIS-guided depth of anesthesia
Number of subjects: 310

Group type: COMPARATOR
Intervention: End‐tidal anesthetic concentration-guided depth of anesthesia
Number of subjects: 310
Study: 21859212

Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention (¡Viva Bien!)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study: 20151087

Group type: EXPERIMENTAL
Intervention: Exclusive + predominant breastfeeding
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Maternal anemia
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Type of flooring at home, type of delivery, birthweight
Number of subjects: 330
Study: 18545188

Group type: EXPERIMENTAL
Intervention: Resistance training for 14 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Detraining for 4 weeks
Number of subjects: 11
Study: 15805999

Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy (SIT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: COMPARATOR
Intervention: Out-seasonal ratings
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: In-seasonal reports
Number of subjects: 35
Study: 12143204

Group type: EXPERIMENTAL
Intervention: Intravenous allopurinol
Number of subjects: 16

Group type: COMPARATOR
Intervention: No allopurinol
Number of subjects: 16
Study: 9804023

Group type: EXPERIMENTAL
Intervention: Amoxicillin + clavulanic acid (Spektramox)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Penicillin-V (Primcillin)
Number of subjects: 386
Study: 7666706

Group type: EXPERIMENTAL
Intervention: Standard gamble method
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Rating scale method
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Chained gambles
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Severe hypothetical state
Number of subjects: 229
Study: 2514810

Group type: EXPERIMENTAL
Intervention: NeoCalme
Number of subjects: 26

Group type: COMPARATOR
Intervention: Valium
Number of subjects: 26
Study: 711799

Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 100

Group type: COMPARATOR
Intervention: No suction drainage (Control)
Number of subjects: 100
Study: 30717830

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Informational pamphlet (IP)
Number of subjects: 30
Study: 29502375

Group type: EXPERIMENTAL
Intervention: Cervical Jiaji electroacupuncture
Number of subjects: 39

Group type: COMPARATOR
Intervention: Metoclopramide combined with chlorpromazine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cervical Jiaji electroacupuncture (for patients who resisted control treatment)
Number of subjects: 39
Study: 26901657

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive behavioral therapy
Number of subjects: 100
Study: 23945999

Group type: EXPERIMENTAL
Intervention: 30 mg hydrocortisone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 22352813

Group type: EXPERIMENTAL
Intervention: Coping-skills training
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard asthma education (attention control)
Number of subjects: 137
Study: 20850039

Group type: EXPERIMENTAL
Intervention: Pectoralis minor soft tissue mobilization (STM) and self‐stretching
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo touch and pectoralis major self‐stretching
Number of subjects: 28
Study: 17178181

Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg q.i.d. on days 1 and 2
Number of subjects: 46
Study: 16078288

Group type: EXPERIMENTAL
Intervention: Consultant general surgeons
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Consultant physicians
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2000
Study: 12072603

Group type: EXPERIMENTAL
Intervention: Cimetidine (H2RA)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 9478092

Group type: EXPERIMENTAL
Intervention: Spontaneous production of interleukin-1 beta by monocytes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: LPS stimulated production of interleukin-1 beta by monocytes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group of 23 healthy males
Number of subjects: 25
Study: 7885295

Group type: EXPERIMENTAL
Intervention: Sensitization to storage mites among cattle farmers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation with mite species in cattle barns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-sensitization to Dermatophagoides
Number of subjects: 0
Study: 3129969

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 29859274

Group type: EXPERIMENTAL
Intervention: Mobile phone based text messaging lifestyle intervention (n=271)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Standard care advice (n=266)
Number of subjects: 394
Study: 28821576

Group type: EXPERIMENTAL
Intervention: Behavioral intervention strategy (theoretical and practical counseling once yearly for 3 years)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Behavioral intervention strategy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 300
Study: 26278651

Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ventricular pacing
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Manual ECG interpretation for atrial pacing
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Manual ECG interpretation for ventricular pacing
Number of subjects: 46
Study: 23207237

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV) application every 6 months
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV) application
Number of subjects: 543
Study: 20948557

Group type: EXPERIMENTAL
Intervention: Dietary counselling with probiotics (Lactobacillus rhamnosus GG and Bifidobacterium lactis)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Dietary counselling with placebo
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control/placebo group
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 256
Study: 18440920

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg qd
Number of subjects: 71

Group type: COMPARATOR
Intervention: Ranitidine 150 mg
Number of subjects: 71
Study: 16956340

Group type: EXPERIMENTAL
Intervention: Fetal pulse oximetry (FPO) added to conventional cardiotocographic (CTG) monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cardiotocographic (CTG) monitoring alone
Number of subjects: 0
Study: 12697884

Group type: EXPERIMENTAL
Intervention: Chemotherapy + RT
Number of subjects: 179

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 179
Study: 10728951

Group type: EXPERIMENTAL
Intervention: Amiodarone (30 mg/kg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 8957727

Group type: EXPERIMENTAL
Intervention: HCl
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: HCl/Pepsin
Number of subjects: 47

Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Patients with RE
Number of subjects: 47